Acadia Pharmaceuticals Inc. announced the appointment of Adora Ndu, Pharm.D., J.D. to its Board of Directors. Dr. Ndu is a biopharma executive with more than 15 years of experience in regulatory affairs and clinical development. Since 2022, Dr. Ndu has served as the Chief Regulatory Affairs Officer of BridgeBio.

Previously, she was the Group Vice President, Head of Worldwide Research and Development Strategy, Scientific Collaborations and Policy at BioMarin Pharmaceutical. She brings over 15 years of complementary experience in drug development and regulatory affairs. Dr. Ndu has spent eight years in various leadership roles in the biopharmaceutical sector.

Her expertise includes regulatory strategy, patient engagement, prescription drug promotion, and policy for U.S. and international markets. Additionally, Dr. Ndu spent eight years at the U.S. Food and Drug Administration, Center for Drug Evaluation and Research, where she progressed in leadership serving most recently as Director for the Division of Medical Policy Development and Commander in the U.S.Public Health Service. She has been involved in the registrations of multiple products globally and is a respected thought leader in regulatory science, having played a significant role in developing and evaluating guidance, as well as shaping regulatory policy.

Dr. Ndu currently serves on the board of DBV Technologies. Dr. Ndu received her doctorate in pharmacy from Howard University's College of Pharmacy and a law degree from the University of Maryland.